Join Roswell Park at AACR 2026 - Scorecard - MDSpire

Join Roswell Park at AACR 2026

Roswell Park experts present updates on their latest groundbreaking research at the American Association for Cancer Research conference, April 17-22, 2026, in San Diego.

  • April 14, 2026

  • 1 min

Share

Clinical Scorecard: Join Roswell Park at AACR 2026

At a Glance

CategoryDetail
ConditionMetastatic Colorectal Cancer and p53-Mutated Solid Tumors
Key MechanismsTargeted therapy vs. standard chemotherapy; p53 mutation strategies
Target PopulationPatients with aggressive metastatic colorectal cancer and p53-mutated solid tumors
Care SettingOncology research and clinical trials

Key Highlights

  • Zunairah Shah, MBBS, presents on targeted therapy outcomes
  • Comparison of targeted therapy and standard chemotherapy
  • Andrei Bakin, PhD, leads research on p53-mutated tumors
  • AACR conference dates: April 17-22, 2026
  • Roswell Park booth #492 for team interactions and job opportunities

Guideline-Based Recommendations

Diagnosis

  • Assess patient eligibility for targeted therapy in metastatic colorectal cancer
  • Evaluate p53 mutation status in solid tumors

Management

  • Consider targeted therapy for aggressive subtypes of metastatic colorectal cancer
  • Explore new treatment strategies for p53-mutated tumors

Monitoring & Follow-up

  • Monitor patient outcomes and side effects of targeted therapies
  • Regularly assess tumor response to treatment

Risks

  • Potential resistance to standard chemotherapy
  • Adverse effects associated with targeted therapies

Patient & Prescribing Data

Patients with aggressive metastatic colorectal cancer and p53 mutations

Targeted therapies may improve outcomes compared to traditional chemotherapy

Clinical Best Practices

  • Utilize genetic testing to guide treatment decisions
  • Engage in multidisciplinary discussions for complex cases
  • Stay updated on emerging therapies and clinical trial results

Related Resources & Content

Original Source(s)

Join Roswell Park at AACR 2026

  • April 14, 2026

Related Content

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

  • 1 min
STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

What starts at UCI Health can help shape the national conversation.

  • June 30, 2026

  • 1 min
Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min